Dickhoff Chris, Otten Rene H J, Heymans Martijn W, Dahele Max
Department of Surgery and Cardiothoracic Surgery, Amsterdam UMC, Cancer Centre Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Medical Library, Vrije Universiteit, Amsterdam, The Netherlands.
Ther Adv Med Oncol. 2018 Oct 5;10:1758835918804150. doi: 10.1177/1758835918804150. eCollection 2018.
Once recurrent or persistent locoregional tumour after radical chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) is identified, few curative-intent treatment options are available. Selected patients might benefit from surgical salvage. We performed a systematic review of the available literature for this emerging treatment option.
A systematic literature search was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Publications about persistent or (locoregional) recurrent disease after radical/definitive CRT for locally advanced non-small cell lung cancer were identified.
Eight full papers were found, representing 158 patients. All were retrospective series and data were heterogeneous: definition and indication for salvage surgery varied and the median time from radiotherapy to surgery was 4.1-33months. Complete resection (R0) was achieved in 85-100%, with vital tumour in 61-100%. A large number of pneumonectomies were performed, and additional structures were often resected. Where reported, 90-day mortality was 0-11.4%. Reported survival metrics varied but included median overall survival 9-46months and 5-year survival 20-75%.
There are limited, low-level, heterogeneous data in support of salvage surgery after radical CRT. Based on this, perioperative mortality appears acceptable and long-term survival is possible in (highly) selected patients. In suitable patients (fit, no distant metastases, tumour appears completely resectable and preferably with confirmed viable tumour), this treatment option should be discussed in an experienced multidisciplinary lung cancer team.
对于非小细胞肺癌(NSCLC)患者,在根治性放化疗(CRT)后一旦发现局部区域肿瘤复发或持续存在,几乎没有治愈性的治疗选择。部分患者可能从挽救性手术中获益。我们对关于这种新兴治疗选择的现有文献进行了系统综述。
根据系统评价和Meta分析的首选报告项目(PRISMA)声明进行系统的文献检索。确定了关于局部晚期非小细胞肺癌根治性/确定性CRT后持续性或(局部区域)复发性疾病的出版物。
找到8篇全文,共158例患者。均为回顾性系列研究,数据异质性较大:挽救性手术的定义和指征各不相同,从放疗到手术的中位时间为4.1至33个月。85%至100%的患者实现了根治性切除(R0),61%至100%的患者存在存活肿瘤。进行了大量的全肺切除术,并且经常切除其他结构。据报告,90天死亡率为0%至11.4%。报告的生存指标各不相同,但包括中位总生存期9至46个月和5年生存率20%至75%。
支持根治性CRT后进行挽救性手术的数据有限、水平较低且存在异质性。基于此,围手术期死亡率似乎可以接受,(经过高度)选择的患者有可能获得长期生存。对于合适的患者(身体状况良好、无远处转移、肿瘤似乎可完全切除且最好有确诊的存活肿瘤),应由经验丰富的多学科肺癌团队讨论这种治疗选择。